Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic
metastasis and intrahepatic lesions that are expected to be radical resected in several
domestic clinical centers, and observe the OS and ORR, DCR, DOR, TTP and PFS of patients
receiving hepatectomy combined with apatinib + carrelli pearl treatment.